DAPA-RWE: a retrospective multicenter study comparing dapagliflozin and sitagliptin in patients with Type 2 diabetes treated under routine clinical practice in Spain
Conclusion: DAPA-RWE confirmed dapagliflozin to be more effective than sitagliptin in reducing HbA1c and weight.PMID:33955233 | DOI:10.2217/cer-2020-0264
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Authors: Cristobal Morales Virginia Bellido Cristina Tejera Fernando Go ñi Rafael Palomares Cristina Sevillano Diego Bellido Alfonso Soto Miguel Ángel Mangas Manuel A Botana Irene Caballero Source Type: research
More News: Dapagliflozin | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Forxiga | General Medicine | Januvia | Obesity | Spain Health | Study